COVID-19 Parental Vaccine Hesitancy in Romania: Nationwide Cross-Sectional Study

Loredana Sabina Cornelia Manolescu 1,2,*, Corneliu Nicolae Zaharia 2, Anca Irina Dumitrescu 3, Irina Prasacu 3, Mihaela Corina Radu 1,4,.*, Adrian Calin Boeru 4, Liliana Boidache 1, Irina Nita 1,5, Andrei Necsulescu 6, Cosmin Medar 7, Corina Marilena Cristache 8* and Razvan Daniel Chivu 9

Abstract: Background: COVID-19 vaccination started in Romania in December 2020. Child vaccination started in 2021 with children aged 12–15 years in August. For children aged 5–11 years, vaccination started in January 2022. The aim of our study was to describe COVID-19 vaccination hesitancy in Romanian children and vaccine acceptability in the general population. As parental consent is required for child vaccination in Romania, these aspects have a significant association. Methods: An analytical cross-sectional survey was conducted in October and November 2021 during the peak of the 4th COVID-19 wave. Results: After validation, 1645 participants formed the main study group: median age 35 years, 72.83% women, and 35.44% from the medical domain. In total, 1311 (79.70%) participants were vaccinated against COVID-19 and 188 (11.42%) had vaccinated their 12–18-year-old children against COVID-19. Parents’ level of education, geographic area of residence, and being a COVID-19-vaccinated parent. Public health intervention programs are essential.

Keywords: COVID-19 vaccination; parental vaccine hesitancy; child vaccination
1. Introduction

For several years, vaccine hesitancy has represented one of the global public health threats [1].

The COVID-19 pandemic has raised vaccine hesitancy to a new level, mostly due to the novelty of the vaccines that have been issued [2].

Parental vaccine hesitancy at international, national, and regional levels may have a great impact on vaccination in general.

COVID-19 vaccination started in Romania in December 2020. A national vaccination campaign was initiated, with the first phase targeting the vaccination of healthcare and social workers [3,4]. As of 28 December 2020, an IT platform, ROVACCINARE, allowed the registration of people for vaccination against COVID-19 (https://programare.vaccinare-covid.gov.ro/; accessed on 20 January 2022). The second phase of the Romanian vaccination campaign targeted people at high risk and the elderly, those aged over 65 years, adults with chronic diseases, and people who are involved in essential activities. The third phase targeted vaccination of the general population and people aged over 16 years, and started on 15 March 2021 [5]. The platform has been operational and allowed the vaccination of children aged 12–15 years old since 1 August 2021 and for individuals receiving the booster (3rd dose) since 28 September 2021 [5]. During the fall of 2021, Romania experienced the fourth wave of COVID-19, with the dominant mutant being the SARS-CoV-2 Delta variant [6]. The peak of new confirmed infections was reached on 18 October with a total of 18,863 new cases. On 2 November, Romania reported 591 deaths on 1 day, with a 7-day average of 454 deaths [5,7].

According to the European Center for Disease Prevention and Control COVID-19 Vaccine Tracker, in Romania, the cumulative uptake of full vaccination in the total population as of 25 January 2022 was 41%, which is still a low value compared with EU/EAA data of 69.7%. The uptake of an additional dose, the 3rd booster dose, in Romania was 7% [7].

On 6 December 2021, the SARS-CoV-2 Omicron variant was detected in Romania, for which the sequencing was performed at the “Cantacuzino” National Institute for Medico-Military Research in Bucharest [8]. Since then, the 5th wave of COVID-19 infection started in Romania and the number of new infections dramatically increased from 349 cases (new confirmed, 25 December 2021) to 34,255 cases (new confirmed, 25 January 2022) [5,9,10], almost 100 times in less than a month.

Although the European Medicines Agency (EMA) recommended that the Pfizer COVID-19 vaccine should be given to children aged 5 to 11 years since 25 November 2021, in Romania, vaccination for this age group only started on 26 January 2022.

Due to the high rate of transmissibility of the Omicron variant, the low rate of vaccination in children of all ages, and for the safety of Romanian children, since December 2021, the Ministry of Health [11] started a testing program in schools using the rapid saliva COVID-19 antigen test. Since then, in Romanian schools, two tests have been required each week, on Mondays and Thursdays.

In Romania, recent studies regarding vaccination, according to the national vaccination program, have shown that a lack of information and fear of side effects has determined parents’ decision to not vaccinate their children in general [12].

Because the vaccination is still the most effective tool against the severe COVID-19 disease, the aim of our study was to assess and discuss COVID-19 vaccination hesitancy in Romanian children because the vaccination of children depends on their parents’ vaccine acceptability. Due to this, we also studies vaccine acceptability in the general population.

2. Materials and Methods

2.1. Study Design, Sites, and Participants

2.1.1. Study Design

An analytical cross-sectional observational survey was conducted in Romania in the general population. For an accurate design, we used “The Strengthening the Reporting of
Observational Studies in Epidemiology” (STROBE) recommendations in our observational study. The STROBE checklist is included in the Supplementary Materials [13].

2.1.2. Study Setting

This study was conducted in Romania in all 41 counties and in the capital, Bucharest, with the aid of volunteers, medical students, and teaching staff from “Carol Davila” University of Medicine and Pharmacy from Bucharest. The students and professors who spread the questionnaire were volunteers and agreed to explain the questionnaire to the public to achieve as many correct answers as possible.

2.1.3. Study Participants

This study was addressed to the general population, all people living in the Romanian counties and the capital. The goal was to collect at least 30 answers from each county. The inclusion criteria for the questionnaire required participants to be 18 years of age or older and living in Romania. The participants were contacted by volunteers, and everybody was welcomed. The domain of activity of the participants was defined as medical and non-medical. The medical domain of activity included medical doctors, nurses, pharmacists, paramedics, midwives, and medical students. We included this category because the medical domain responders may have influence over the general population regarding vaccination, and they are a key factor in vaccine importance education. The non-medical domain included all types of professions unrelated to the medical ones. The level of education was reflected by the level of completed studies, including high school, post-secondary school, and university/post-university studies.

2.2. Survey Questionnaire and Data Collection

Data were collected with the use of a self-administered questionnaire. The questionnaire was administered online for 2 months: October and November 2021, during the peak of the COVID-19 4th wave (and with the known threat of the emergence of the 5th COVID-19 wave), and because of the epidemiological situation, people were eager to help in any way to resolve the COVID-19 situation, resulting in a good response rate. The questionnaire (which can be found in the Supplementary Materials File S1) comprised 19 multiple choice questions divided into sections (general information and information about the COVID-19 vaccine). It was distributed by volunteers through media messages, both individually and in institutional communication groups in the form of a link. After it was issued in Google Forms, informed consent was required and obtained from each willing participant, and the responder was initially informed of the purpose of the survey. The questionnaire could only be submitted after all its questions were answered.

2.3. Ethical Approval

The questionnaire was peer-validated and approved by the Ethics Committee of the Obstetrics and Gynecology Hospital, Ploiești, Romania (14325/21.12.2020); all the procedures in the study respected the ethical standards of the Helsinki Declaration. Informed consent was compulsory.

2.4. Statistical Analysis

For statistical analysis, we used the Microsoft Office package Excel and IBM® SPSS® Statistics Version 23.0 software. For data processing, the COUNTIFS function in Excel was used to filter and sort the initial database. Categorical variables on the sociodemographic characteristics of the parents were expressed using descriptive statistics and frequencies. The chi-squared test (for categorical variables) and measures of association (φ-test) were used to determine the parental characteristics associated with their willingness to vaccinate children under the age of 18 years with the COVID-19 vaccine.
We used logistic regression to analyze the factors (level of education, geographic area, vaccination status of the parent) that influenced the odds of children being vaccinated. The level of significance was set to 0.05.

3. Results

In total, 1650 individual answers were gathered. The answers to the questions are summarized in the Supplementary Materials File S2. The first part of the survey targeted general data to characterize the group. We excluded five participants due to incomplete answers regarding their age, vaccine status, and profession. After validating the rest, 1645 participants remained. The mean age of the participants was 34.91 ± 12.58 years (limits: 18–77), with a median of 35 years, and 1198 (72.83%) of the participants were women. Of our group of 1645 participants, 583 (35.44%) were from the medical domain. Most of the participants in the survey lived in an urban geographic area (1343, 81.64%) and had completed post-university studies (740, 45.63%). The general characteristics of the survey participants are summarized in Table 1.

Table 1. Vaccination/infectious COVID-19 status, socio-demographic, and educational characteristics of the respondents to the questionnaire.

| Characteristics                        | N = 1645 |
|----------------------------------------|----------|
| Vaccinated against COVID-19            | 1311 (79.70%) |
| Not infected with SARS-CoV-2           | 381 (23.23%) |
| Gender (women)                         | 1198 (72.83%) |
| Age (median, min-max)                  | 35 (18–77) |
| Geographic area (urban)                | 1343 (81.64%) |
| Family status: married                 | 763 (46.38%) |
| Domain of activity: medical            | 583 (35.44%) |
| Level of education                     | 607 (36.97%) |
| High school                            | 487 (29.60%) |
| Post-secondary school                  | 109 (6.63%) |
| University/post-university studies     | 1032 (62.74%) |
| Have children                          | 792 (48.15%) |

In the whole study group, 1311 (79.70%) participants were vaccinated against COVID-19 but only 188 (11.42%) participants had vaccinated their children aged from 12–18 years, as shown in Table 2. Our survey was conducted during a period when COVID-19 vaccination of children aged 5–11 years was not available in Romania.

Table 2. Vaccination/infectious COVID-19 status, socio-demographic, and educational characteristics of respondents who had vaccinated their children (12–18 years).

| Characteristics                        | N = 188 |
|----------------------------------------|----------|
| Not infected with SARS-CoV-2           | 124 (65.96%) |
| Gender (women)                         | 144 (76.6%) |
| Age (median, min-max)                  | 46 (28–68) |
| Geographic area (urban)                | 157 (83.51%) |
| Family status: married                 | 150 (79.79%) |
| Vaccinated against COVID-19            | 183 (97.34%) |
| Level of education                     | 60 (32.22%) |
| High school                            | 17 (9.04%) |
| Post-secondary school                  | 18 (9.57%) |
| University/post-university studies     | 150 (79.79%) |
| Domain of activity: medical            | 80 (42.55%) |

Some of the study variables, after stepwise selection, were significantly associated with COVID-19 vaccination of children aged between 12 and 18 years. From the logistic regression analysis, level of education (ORa = 0.546; 95% CI: (0.321; 0.927)), geographic area
of residence (ORa = 0.669; 95% CI: (0.369; 1.215)), and being a COVID-19-vaccinated parent
(ORa = 0.032; 95% CI: (0.013; 0.082)) (Table 3) were significantly associated with willingness
to vaccinate children.

Table 3. Logistic regression model for COVID-19 vaccination of children aged between 12 and
18 years.

|                                | B    | E.S. | Wald     | p     | ORa  | Lower CI 95% | Upper CI 95% |
|--------------------------------|------|------|----------|-------|------|--------------|--------------|
| COVID-19 vaccination status of the parent | -3.440 | 0.480 | 51.447   | 0.000 | 0.032 | 0.013        | 0.082        |
| Level of education (university and more vs. high school and secondary school) | -0.606 | 0.271 | 5.014    | 0.025 | 0.546 | 0.321        | 0.927        |
| Geographic area (urban vs. rural) | -0.401 | 0.304 | 1.740    | 0.187 | 0.669 | 0.369        | 1.215        |
| Constant                        | 0.934 | 0.155 | 36.272   | 0.000 | 2.544 |              |              |

Between 26.7% and 35.7% of variance of the child vaccination is explained by the
following variables: level of education of the parent, geographic area, and vaccinated/non-
vaccinated parent (Table 4).

Table 4. Variance of child vaccination.

|                                | Cox and Snell R Square | Nagelkerke R Square |
|--------------------------------|-------------------------|---------------------|
|                                | 0.267                   | 0.357               |

Because children aged between 12 and 18 years need their parents’ consent for im-
umunization in Romania, we considered the discovery of all factors that may influence the
decision to vaccinate a child against COVID-19 critical. In our study group, 792 (48.15%)
participants had children, but out of them, only 319 (19.39%) participants had children aged
between 12 and 18 years. The remaining 473 (28.75%) participants had younger children. In
total, 188 (11.42%) participants matched all the discussed criteria, and their children were
aged between 12 and 18 years and were immunized against COVID-19. Vaccination was
also recommended for children aged 5 to 11 years when the vaccination was available, as
shown in Table 5. The variables that were significantly associated with COVID-19 vacci-
nation in the 12–18-years age group were also used in the cases of children aged between
5 and 11 years: level of education (ORa = 0.494; 95% CI: (0.313; 0.779)), geographic area
of residence (ORa = 0.591; 95% CI: (0.355; 0.984)), and COVID-19 vaccination status of the
parent (ORa = 31.440; 95% CI: (12.336; 80.128)).

Table 5. Logistic regression model for COVID-19 vaccination of children aged between 5 and 11 years.

|                                | B    | E.S. | Wald     | p     | ORa  | Lower CI 95% | Upper CI 95% |
|--------------------------------|------|------|----------|-------|------|--------------|--------------|
| Level of education (university and more vs. high school and secondary school) | -0.706 | 0.233 | 9.208    | 0.002 | 0.494 | 0.313        | 0.779        |
| Constant                        | 0.324 | 0.122 | 7.004    | 0.008 | 1.383 |              |              |
| Geographic area (urban vs. rural) | -0.526 | 0.260 | 4.081    | 0.043 | 0.591 | 0.355        | 0.984        |
| Constant                        | 0.231 | 0.115 | 3.999    | 0.046 | 1.259 |              |              |
| COVID-19 vaccination status of the parent | 3.448 | 0.477 | 52.184   | 0.000 | 31.440 | 12.336      | 80.128       |
| Constant                        | -2.760 | 0.461 | 35.821   | 0.000 | 0.063 |              |              |

Among the participants who had children in the 12–18-years age group and did not
vaccinate their children against COVID-19, 131 (7.96%) participants stated the following
reasons for not immunizing their children: they considered the COVID-19 vaccines too
new and that they needed to be studied more (62, 47.32%), they were afraid of the adverse
reactions of the COVID-19 vaccines (32, 24.42%), they did not agree with vaccination in general (29, 22.13%), or they believed that is better to be immunized naturally, i.e., by being infected and having COVID-19 disease (8, 6.10%).

Regarding the vaccine acceptability in the general population, as shown in Table 1, we believe that the Romanian population understood the important need for COVID-19 vaccination. Out of 1645 participants, 1311 (79.70%) were immunized. In our study, vaccine acceptability was higher in the general population (79.70%) than among healthcare workers from the medical domain (55.91%), with 326 out of 583 indicating acceptability. The Romanian population have access to all types of approved COVID-19 vaccines in the European Union. Most of the vaccinated participants (1104, 84.21%) were immunized with mRNA vaccines. Out of the 1311 vaccinated participants, 482 (36.76%) experienced adverse reactions after receiving the vaccination, such as pain at the site of injection, inflammation at the site of injection, fever, and/or chills. The factors underlying vaccine hesitancy among adults included the belief that the vaccine was not effective (131, 39.22%), fears regarding the side effects of the vaccine (76, 22.75%), the belief that it is more useful to make antibodies by acquiring the disease than being vaccinated (57, 17.06%), disagreeing with vaccination in general (35, 10.47%), and passing through the COVID-19 disease (11, 3.29%). The characteristics of the two groups: COVID-19-vaccinated and non-COVID-19-vaccinated participants, are presented in Table 6. There were no statistical differences between the two groups.

Table 6. Characteristics of COVID-19-vaccinated and non-vaccinated participants in the survey.

| Characteristics               | COVID-19 Vaccinated N = 1311; 79.69% | COVID-19 Not Vaccinated N = 334; 20.30% |
|------------------------------|-------------------------------------|----------------------------------------|
| Age                          | Mean 35.44                          | 32.84                                  |
|                              | Standard Deviation 12.82             | 11.38                                  |
|                              | Median (Min/Max) 35 (18/77)          | 35 (36/63)                             |
| Gender                       | Women 931 (71.01%)                   | 236 (70.65%)                           |
|                              | Man 350 (26.69%)                     | 98 (29.34%)                            |
| Geographic area              | Urban 1086 (82.83%)                  | 259 (77.54%)                           |
|                              | Rural 225 (17.16%)                   | 75 (22.45%)                            |
| Family status                | Married 616 (46.98%)                 | 147 (44.01%)                           |
|                              | Single 695 (53.01%)                  | 187 (55.98%)                           |
| Level of education           | Lower 473 (36.07%)                   | 141 (42.21%)                           |
|                              | high 838 (63.92%)                    | 193 (57.78%)                           |
| Infected with SARS-CoV2      | Yes 413 (31.50%)                     | 166 (49.70%)                           |
|                              | No 898 (68.49%)                      | 168 (50.29%)                           |
| Domain of activity           | Medical 326 (24.86%)                 | 257 (76.94%)                           |
|                              | Other 985 (75.13%)                   | 77 (23.05%)                            |
| Do you have children?        | Yes 642 (48.97%)                     | 150 (44.91%)                           |
|                              | No 669 (51.02%)                      | 184 (55.08%)                           |

After 6 months of complete immunization, the Romanian population could receive a third booster dose. In our group, from the 1311 COVID-19-vaccinated participants, 404 (30.81%) received the 3rd booster dose. All participants with the booster dose received an mRNA COVID-19 vaccine. The remaining participants declared either that they had no
intention of receiving the booster dose (405, 30.89%) or that they will do it in the future (502, 38.29%). Most of the 404 participants that received the 3rd booster dose developed a minor adverse reaction, such as pain at the site of injection (341, 84.40%) or enlargement of the axillary lymph nodes (63, 15.59%).

4. Discussion

The COVID-19 vaccine could represent the best hope to end the pandemic and a key factor in resolving the sanitary crisis. Scientists have competed in the development of vaccines in unprecedented joint efforts within the scientific community. However, as seen in the context of other diseases in humans, agriculture, and wildlife, the challenge of eradicating the spread of a disease does not end with the discovery of an effective vaccine. The implementation of the vaccination program is extremely important. Here, we aimed to assess the acceptability of the COVID-19 vaccine in the Romanian adult population and the willingness of Romanians to vaccinate their children as the COVID-19 vaccines became available in Romania for different age groups, thus documenting COVID-19 vaccination in Romanian children. We also explored the socio-demographic variables of the vaccinated and non-vaccinated participants in our studied groups and their COVID-19 vaccine beliefs.

At the global level, studies have highlighted a hesitancy to vaccinate children using different vaccine types in general [14–20]. This hesitancy to vaccinate translates to severe consequences. Moreover, beliefs in conspiracy theories, distrust in science and decision-makers, and distrust in official channels of information may also increase hesitation regarding vaccination. Understanding their causes could improve our ability to respond to the pandemic. Various impressions of adverse events associated with vaccines have been experienced in Romania, which are mostly scandals based upon undocumented fears, leading to a loss of public confidence in vaccines [21,22].

Several studies have warned against misinformation against COVID-19 vaccines, which can be easily spread through social media, requiring collaborative efforts by governments, health decision-makers, and media sources to spread clear and timely messages that support the safety and efficacy of currently available COVID-19 vaccines. This promotes vaccines and builds confidence in COVID-19 vaccination among the general public [23–26].

We believe the same happened here as 22.75% (76 out of 334), of the unvaccinated participants reported concerns about the possible side effects of the COVID-19 vaccine. Some parents questioned the need to vaccinate their children, which was often based on medical events temporarily associated with the vaccination, which happened to family members or friends/acquaintances or were reported in newspapers, TV shows, the internet, etc. Anti-vaccination groups are widely publicized and attempt to convince parents that avoiding vaccination is safe and effective [21,22,27,28].

Social networks must not harm the prevention and control of infectious diseases. Their potential can be exploited with public health interventions, reaping significant benefits. In the case of vaccination, in Romania, social media platforms have become an important vector in providing accurate scientific information. For example, Romania has the largest Facebook group in the world, which provides parents vaccination tips directly from primary care physicians [29,30]. Given this, the use of such social media platforms will prove beneficial in addressing the vaccine hesitation in Romania, thus helping to implement any potential anti-COVID-19 immunization strategy.

In Romania, by the end of December 2020, there were over half a million documented SARS-CoV-2 infections. The actual figures probably far exceeded this figure due to insufficient testing [31]. Despite these data, our study showed a good level of acceptability of the COVID-19 vaccination among the population under study (1311, 79.69%) but a low level of vaccinated children (188, 11.42%). This justifies the low figures indicating about 8 million vaccinated people, with only 2 million people obtaining the booster dose and only 2113 vaccinated children, according to the ROVACCINARE-Platform [5]. Previous research has shown that high population sensitivity and high-risk perception of the disease are associated with better pandemic control [32]. Thus, prevention and control measures
should be encouraged. The perceived barriers against COVID-19 immunization found in this study, namely concerns about side effects and the efficacy of the vaccine, have also been reported in other studies related to the introduction of a new vaccine [33]. This study was conducted just before the emergence of the Omicron strain, a strain that, according to studies, affects a younger population. Studies have shown that children generally develop mild symptoms and can experience robust effects with high levels of SARS-CoV-2 replication, thus significantly contributing to viral spread [34].

In this study, despite a large proportion of participants (872, 53.01%) expressing an intention to vaccinate their children, a significant percentage did not have this intention (773, 46.99%). Uncertainties about the safety of the vaccine, and the efficacy and benefits of vaccinating children were the most widespread reasons cited for parents’ refusal of the COVID-19 vaccine.

Several recent studies showed similar levels of vaccine acceptability in the general population, such as 71.4% (1878 responders) in a study from Mozambique [35] vs. 79.70% (1645 responders) in our study. Some differences regarding the reasons underlying vaccine hesitancy include fears about the vaccine’s side effects (29.6% in the Mozambique study vs. 22.75% in our study) and the belief that the vaccine is not effective (52% in the Mozambique study vs. 39.22% in our study). In the Mozambique study, vaccine acceptability was relatively high among healthcare workers but significantly lower in the rest of the population. This finding was different from our study, where vaccine acceptability in the medical domain was 55.91% lower than in the general population (79.70%), as reported in Romanian studies [4,35]. The Romanian population is very cautious when it comes to science. In our study, most of the participants did not trust COVID-19 vaccines, as they considered COVID-19 vaccines have not been adequately researched (62, 47.32%), which was not encountered in either Polish or Saudi Arabian studies [36,37]. Another predictor of vaccine hesitancy appears to reside in beliefs in conspiracy theories [36,38], which was not encountered in our study. Findings from UK studies revealed that age and ethnicity were the only sociodemographic factors to predict vaccine hesitancy, which was again different from our findings [39].

Similar to Italian studies in the Romanian population, mRNA vaccines were preferred for the initial vaccination and booster dose [40].

The COVID-19 pandemic has disrupted the lives of millions of children across the world for several reasons. The COVID-19 vaccination could end this [41,42] with the help of parents because in Romania, child vaccination is only possible with parents’ permission, so vaccination’s acceptability in the general population is critical.

Studies from Australia, conducted at the same time as our study [43], showed that vaccine intention increased in the last months of 2021 in the general population but not among children. Similar to our findings, parents who intended to vaccinate themselves (OR: 0.599, 95% CI: (0.367–0.980)) reported greater acceptance of their children being vaccinated in a Saudi Arabia study [44].

From our findings, the level of education of participants (ORa = 0.494; 95% CI: (0.313; 0.779)) was significantly associated with COVID-19 vaccination in children aged between 5 and 11 years, which is similar to other findings [45] and contrary to others [46].

In children of all ages, either the 12–18-year or 5–11-year groups, vaccine hesitancy has been identified all over the world [47,48].

**Limitation of the Study**

This study was subject to several potential limitations. Firstly, this study was limited by its cross-sectional design. Consequently, the representativeness of the study sample is limited due to the default selection of respondents who have digital skills as the studied sample only contained people who could use the internet and electronic documents. This is also supported by the age of the respondents, who had a median age of 35 years, and the questionnaire format, which was a Google Form questionnaire that was accessed by a link and electronically self-administered. Secondly, another limitation of this study
is that it only analyzed only a short time period of 2 months, October and November 2021, and included a limited number of participants with children (792, 48.15%). It is possible that people’s acceptability of child vaccination may change over time as major news about vaccines appears daily, and political circumstances and epidemiological data change; therefore, longitudinal monitoring is indicated. Third, there are some limitations regarding the place of residence, as 81.64% of our studied group lived in an urban area, and 35.44% of the studied participants worked in the medical domain. Nevertheless, this may not, in fact, be a limitation because these people are opinion formers and may support children’s vaccination.

5. Conclusions

The findings of this study suggest a high perception of barriers preventing and a low perception of benefits in receiving the COVID-19 vaccines in Romanian children. The factors that influenced children’s vaccination included the level of education, the area of residence, and the vaccination status of the parent. Child vaccination hesitancy was driven by the novelty of COVID-19 vaccines, fears about adverse reactions, and anti-vaccinism in general. Overall, the acceptability of COVID-19 vaccines in the Romania population was influenced by the level of education and area of residence. The vaccine’s acceptability in the medical domain was lower than in the general population. General vaccine hesitancy was based mainly on the beliefs about inefficiency and fears about the side effects of the vaccine.

Therefore, public health intervention programs that focus on raising the awareness of the benefits of vaccination and reducing identified barriers are essential. It is therefore important to provide adequate information to the public, particularly to explain the importance of COVID-19 vaccination and to provide sound evidence regarding the safety and efficacy of the vaccine to support personal and media coverage.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines10040493/s1, File S1: vaccination questionnaire; File S2: questionnaire response; File S3: STROBE-checklist.

**Author Contributions:** Conceptualization, L.S.C.M. and C.M.C.; methodology, L.S.C.M. and L.B.; software, A.I.D. and A.C.B.; validation, I.P. and R.D.C.; formal analysis, I.N.; investigation, A.N.; resources, C.N.Z.; data curation, M.C.R.; writing—original draft preparation, L.S.C.M.; writing—review and editing, I.P. and C.M.C.; visualization, A.I.D. and C.M.; supervision, R.D.C.; project administration, L.S.C.M.; funding acquisition, C.N.Z. All authors have equally contributed to the writing and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This paper was supported by the STAMINA project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 883441.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of (protocol code 14325 and date of approval 21.12.2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Acknowledgments:** All authors have equally contributed to the writing and editing of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* 2015, 33, 4161–4164. [CrossRef] [PubMed]
2. Trogen, B.; Pirofski, L.-A. Understanding vaccine hesitancy in COVID-19. *Med* 2021, 2, 498–501. [CrossRef] [PubMed]
3. Radu, M.C.; Boeru, C.; Marin, M.; Manolescu, L.S. SARS-CoV-2 Infection in Seven Childbearing Women at the Moment of Delivery, a Romanian Experience. *Cureus* 2021, 13, e12811. [CrossRef] [PubMed]
4. Manolescu, L.S.C.; Zaharia, C.N.; Dumitrescu, A.I.; Prasacu, I.; Radu, M.C.; Boeru, A.C.; Boidache, L.; Nita, I.; Neculescu, A.; Chivu, R.D. Early COVID-19 Vaccination of Romanian Medical and Social Personnel. *Vaccines* 2021, 9, 1127. [CrossRef]
5. The Platform for Online Vaccination Appointment | COVID Vaccination (gov.ro). Available online: https://vaccinare-covid.gov.ro (accessed on 20 January 2022).

6. Hohan, R.; Milu, P.; Parasciv, S.; Casangiu, C.; Tudor, A.; Vlaicu, O.; Banica, L.; Surleac, M.; Florea, D.; Otelea, D. The Predictive Value of Mutation Screening for Anticipating COVID-19 Waves. Pathogens 2021, 10, 1464. [CrossRef] [PubMed]

7. European Centre for Disease Prevention and Control COVID-19 Vaccine Tracker. Available online: https://covid19-eu.ecdc.europa.eu/public/extensions/COVID-19-vaccine-tracker.html#uptake-tab (accessed on 25 January 2022).

8. Sequencing of the SARS-CoV-2 Virus Genome in Romania. Available online: https://cantisuzino.mapn.ro/ (accessed on 25 January 2022).

9. Coronavirus (COVID-19) Statistics. Available online: https://www.bing.com/search?q=Coronavirus+statistics (accessed on 25 January 2022).

10. COVID-19 Weekly Surveillance Report. Available online: http://www.cnscbt.ro/ (accessed on 25 January 2022).

11. Press Release. Available online: http://www.ms.ro/ (accessed on 25 January 2022).

12. Popa, G.L.; Muntean, A.-A.; Muntean, M.-M.; Popa, M.I. Knowledge and Attitudes on Vaccination in Southern Romanians: A Cross-Sectional Questionnaire. Vaccines 2020, 8, 774. [CrossRef]

13. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandebroucke, J.P.; The STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [CrossRef]

14. Dubé, E.; Laberge, C.; Guay, M.; Bramadat, P.; Roy, R.; Bettinger, J. Vaccine hesitancy: An overview. Hum. Vaccines Immunother. 2013, 9, 1763–1773. [CrossRef]

15. Dragomirescu, C.C.; Lixandru, B.E.; Palade, A.M.; Baltoiu, M.; Dinu, S.; Cristea, V.C.; Manolescu, L.; Popa, M.I. Comparative analysis of different phenotypic and molecular methods used for the taxonomic identification of Corynebacterium spp. Isolated from clinical samples in Romania. Rom. Biotechnol. Lett. 2017, 22, 12926.

16. Dragomirescu, C.C.; Lixandru, B.E.; Coldea, I.L.; Cornell, O.N.; Pana, M.; Palade, A.M.; Cristea, V.C.; Suciu, I.; Suciu, G.; Manolescu, L.; et al. Antimicrobial Susceptibility Testing for Corynebacterium Species Isolated from Clinical Samples in Romania. Antibiotics 2020, 9, 31. [CrossRef]

17. Manolescu, L.; Mitran, C.; Mitran, M.; Roxana, S.; Mircea, S.; Suciu, I.; Suciu, G.; Preda, M.; Dragomirescu, C.; Popa, G.; Nita, I.; et al. Knowledge, attitude and perception towards the HPV infection and immunization among Romanian medical students. Rom. Arch. Microbiol. Immunol. 2021, 80, 22–34. [CrossRef]

18. Nita, I.; Nitipir, C.; Toma, S.A.; Limbău, A.M.; Pirvu, E.; Bădarău, I.A.; Suciu, I.; Suciu, G.; Manolescu, L. Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study. Medicina 2020, 56, 600. [CrossRef] [PubMed]

19. Nita, I.; Nitipir, C.; Toma, S.A.; Limbău, A.M.; Pirvu, E.; Bădarău, I.A.; Suciu, I.; Suciu, G.; Manolescu, L. Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study. Healthcare 2021, 9, 277. [CrossRef] [PubMed]

20. Radu, M.C.; Boeru, C.; Marin, M.L.; Manolescu, L.S. Diabetes Mellitus and Pregnancy. In Proceedings of the 6th International Conference on Interdisciplinary Management of Diabetes Mellitus And Its Complications (Interdiab), Bucharest, Romania, 5–7 March 2020; pp. 280–287.

21. Iordachescu, F. Questions and problems in child vaccination. Rev. Romana Med. Lab. 2013, 59, 1337–1340. [CrossRef]

22. Manolescu, L.; Temereanca, A.; Diaconu, C.C.; Ruta, S. Correlation between resistance profile and immunosuppression in heavily treated HIV-1 infected Romanian patients. Rom. Biotechnol. Lett. 2011, 16, 6439–6449. [PubMed]

23. Riad, A.; Abdulqader, H.; Morgado, M.; Dommori, S.; Košćik, M.; Mendes, J.J.; Klugar, M.; Kateeb, E.; on behalf of IADS-SCORE. Global Prevalence and Drivers of Dental Students’ COVID-19 Vaccine Hesitancy. Vaccines 2021, 9, 566. [CrossRef]

24. Riad, A.; Jouzová, A.; Ustün, B.; Lagová, E.; Hruban, L.; Janků, P.; Pokorná, A.; Klugarová, J.; Košćik, M.; Klugar, M. COVID-19 Vaccine Acceptance of Pregnant and Lactating Women (PLW) in Czechia: An Analytical Cross-Sectional Study. Int. J. Environ. Res. Public Health 2021, 18, 13373. [CrossRef]

25. Riad, A.; Pokorná, A.; Antalová, N.; Krobot, M.; Zviadadze, N.; Serdiuk, I.; Košćik, M.; Klugar, M. Prevalence and Drivers of COVID-19 Vaccine Hesitancy among Czech University Students: National Cross-Sectional Study. Vaccines 2021, 9, 948. [CrossRef]

26. Sallam, M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines 2021, 9, 160. [CrossRef]

27. Manolescu, L.; Marinescu, P. Sex differences in HIV-1 viral load and absolute CD4 cell count in long term survivors HIV-1 infected patients from Giurgiu, Romania. Rev. Romana Med. Lab. 2013, 21, 217–224. [CrossRef]

28. Marinescu, P.; Manolescu, L.S.C. Association of hepatitis B infection in patients with HIV Encephalopathy. Rom. Biotechnol. Lett. 2012, 17, 7817–7824. [CrossRef]

29. Vaccines and Vaccination—Clarifications and Support for Parents. Facebook. 2020. Available online: https://www.facebook.com/groups/vaccinuri/ (accessed on 29 January 2022).
30. Neagu, A. The Story of the Romanian Who Founded the Largest Pro-Vaccination Group on the Internet: We All Have a Responsibility for Those around US. Available online: https://www.hotnews.ro/stiri-sanatate-23191049-video-interviu-povestea-romanului-care-fondat-ceil-mai-mare-grup-pro-vaccinare-internet-tot-i-am-responsabilitate-pentru-cei-din-jur-vazut-vanzator-ulei-sarpe-pseudo-tratament-care-are-propria-emisiun.htm/ (accessed on 29 January 2022).

31. Dascalu, S.; Geambasu, O.; Covaciu, O.; Chereches, R.M.; Diaconu, G.; Dumitra, G.G.; Gheorghita, V.; Popovici, E.D. Prospects of COVID-19 Vaccination in Romania: Challenges and Potential Solutions. Front. Public Health 2021, 90. [CrossRef]

32. Verelst, F.; Willem, L.; Beutels, P. Behavioural change models for infectious disease transmission: A systematic review (2010–2015). J. R. Soc. Interface 2016, 13, 20160820. [CrossRef] [PubMed]

33. Mullard, A. COVID-19 vaccine development pipeline gears up. Lancet 2020, 395, 1751–1752. [CrossRef]

34. Elliott, P.; Bodinier, B.; Eales, O.; Wang, H.; Daw, D.; Elliott, J.; Whitaker, M.; Jonnerby, J.; Tang, D.; Walters, C.E.; et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. medRxiv 2021. [CrossRef] [PubMed]

35. Dula, J.; Mulhanga, A.; Nhanombe, A.; Cumbi, L.; Júnov, A.; Gwatsvaira, J.; Fodjo, J.N.S.; Faria de Moura Villela, E.; Chicumbe, S.; Colebunders, R. COVID-19 Vaccine Acceptability and Its Determinants in Mozambique: An Online Survey. Vaccines 2021, 9, 828. [CrossRef] [PubMed]

36. Sowa, P.; Kiszkiel, L.; Laskowski, PP.; Alimowski, M.; Szczerbiński, Ł.; Paniczko, M.; Moniuszko-Malinowska, A.; Kamiński, K. COVID-19 Vaccine Hesitancy in Poland—Multifactorial Impact Trajectories. Vaccines 2021, 9, 876. [CrossRef] [PubMed]

37. Mahmud, I.; Kabir, R.; Rahman, M.A.; Alradie-Mohamed, A.; Vinnakota, D.; Al-Mohaimeed, A. The Health Belief Model Predicts Intention to Receive the COVID-19 Vaccine in Saudi Arabia: Results from a Cross-Sectional Survey. Vaccines 2021, 9, 864. [CrossRef] [PubMed]

38. Bertin, P.; Nera, K.; Delouvée, S. Conspiracy Beliefs, Rejection of Vaccination, and Support for hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19 Pandemic Context. Front. Psychol. 2020, 11, 565128. [CrossRef]

39. Cook, E.J.; Elliott, E.; Gaitan, A.; Nduka, I.; Cartwright, S.; Egbutah, C.; Randhawa, G.; Waqar, M.; Ali, N. Vaccination against COVID-19: Factors That Influence Vaccine Hesitancy among an Ethnically Diverse Community in the UK. Vaccines 2022, 10, 106. [CrossRef]

40. Salerno, L.; Craxi, L.; Amodio, E.; Lo Coco, G. Factors Affecting Hesitancy to mRNA and Viral Vector COVID-19 Vaccines among College Students in Italy. Vaccines 2021, 9, 927. [CrossRef]

41. Murewanhema, G.; Mukwena, S.; Dzinamarira, T.; Mukandavire, Z.; Cuadros, D.; Madziva, R.; Chingombe, I.; Mapingure, M.; Herrera, H.; Musuka, G. Optimising COVID-19 Vaccination Policy to Mitigate SARS-CoV-2 Transmission within Schools in Zimbabwe. Vaccines 2021, 9, 1481. [CrossRef] [PubMed]

42. Stein, M.; Ashkenazi-Hoffnung, L.; Greenberg, D.; Dalal, I.; Livni, G.; Chapnick, G.; Stein-Zamir, C.; Ashkenazi, S.; Hecht-Sage, L.; Grossman, Z. The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines 2022, 10, 81. [CrossRef] [PubMed]

43. Heath, K.; Altermatt, A.; Saich, F.; Pedrana, A.; Fletcher-Larrey, S.; Bowring, A.L.; Stoové, M.; Danchin, M.; Kaufman, J.; Gibney, K.B.; et al. Intent to Be Vaccinated Against COVID-19 in Victoria, Australia. Vaccines 2022, 10, 209. [CrossRef] [PubMed]

44. Ennaceur, S.; Al-Mohaithel, M. Parents’ Willingness to Vaccinate Children against COVID-19 in Saudi Arabia: A Cross-Sectional Study. Vaccines 2022, 10, 156. [CrossRef]

45. Bono, S.A.; Siau, C.S.; Chen, W.S.; Low, W.Y.; Faria de Moura Villela, E.; Pengpid, S.; Hasan, M.T.; Sessou, P.; Ditekemena, J.D.; Amodan, B.O.; et al. Adults’ Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries. Vaccines 2022, 10, 11. [CrossRef]

46. Pan, F.; Zhao, H.; Nicholas, S.; Maitland, E.; Liu, R.; Hou, Q. Parents’ Decisions to Vaccinate Children against COVID-19: A Scoping Review. Vaccines 2021, 9, 1476. [CrossRef]

47. Russo, L.; Croci, I.; Campagna, I.; Pandolfi, E.; Villani, A.; Reale, A.; Barbieri, M.A.; Raponi, M.; Gesualdo, F.; Tozzi, A.E. Intention of Parents to Immunize Children against SARS-CoV-2 in Italy. Vaccines 2021, 9, 1469. [CrossRef]

48. Fisher, C.B.; Gray, A.; Scheck, I. COVID-19 Pediatric Vaccine Hesitancy among Racially Diverse Parents in the United States. Vaccines 2022, 10, 31. [CrossRef]